Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use

被引:396
作者
Duffy, M. J.
van Dalen, A.
Haglund, C.
Hansson, L.
Holinski-Feder, E.
Klapdor, R.
Lamerz, R.
Peltomaki, P.
Sturgeon, C.
Topolcan, O.
机构
[1] St Vincents Univ Hosp, Nucl Med Lab, Dept Pathol & Lab Med, Dublin 4, Ireland
[2] UCL, Conway Inst Biomol & Biomed Res, Sch Med & Med Sci, London WC1E 6BT, England
[3] Inst Tumour Marker Oncol, NL-2801 TG Gouda, Netherlands
[4] Univ Helsinki, Cent Hosp, Dept Surg, FIN-00014 Helsinki, Finland
[5] Akad Hosp, Dept Clin Chem & Pharmacol, Uppsala, Sweden
[6] Univ Munich, Dept Med Genet, D-80539 Munich, Germany
[7] Ctr Clin & Expt Tumour Diag & Therapy, Hamburg, Germany
[8] Univ Munich, Klinikum Grosshadern Med Klin 2, D-8000 Munich, Germany
[9] Univ Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland
[10] Royal Infirm, Dept Clin Biochem, Edinburgh EH3 9HB, Midlothian, Scotland
[11] Univ Hosp, Dept Internal Med 2, Plzen, Czech Republic
关键词
colorectal cancer; CEA; guidelines; tumour markers; EGTM;
D O I
10.1016/j.ejca.2007.03.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of this article is to present updated guidelines for the use of serum, tissue and faecal markers in colorectal cancer (CRC). Lack of specificity and sensitivity preclude the use of all existing serum markers for the early detection of CRC. For patients with stage Il or stage III CRC who may be candidates for either liver resection or systemic treatment should recurrence develop, CEA should be measured every 2-3 months for at least 3 years after diagnosis. insufficient evidence exists to recommend routine use of tissue factors such as thymidylate synthase, microsatellite instability (MSI), p53, K-ras and deleted in colon cancer (DCC) for either determining prognosis or predicting response to therapy in patients with CRC. Microsatellite instability, however, may be used as a pre-screen for patients with suspected hereditary non-polyposis colorectal cancer. Faecal occult blood testing but not faecal DNA markers may be used to screen asymptomatic subjects 50 years or older for early CRC. (C) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1348 / 1360
页数:13
相关论文
共 99 条
[1]  
Aarnio M, 1999, INT J CANCER, V81, P214, DOI 10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8>3.3.CO
[2]  
2-C
[3]   Colorectal cancer screening by detection of altered human DNA in stool: Feasibility of a multitarget assay panel [J].
Ahlquist, DA ;
Skoletsky, JE ;
Boynton, KA ;
Harrington, JJ ;
Mahoney, DW ;
Pierceall, WE ;
Thibodeau, SN ;
Shuber, AP .
GASTROENTEROLOGY, 2000, 119 (05) :1219-1227
[4]   Role of genomic markers in colorectal cancer treatment [J].
Allen, WL ;
Johnston, PG .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (20) :4545-4552
[5]  
Anderson WF, 2002, JNCI-J NATL CANCER I, V94, P1126
[6]   Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, J ;
Dix, BR ;
Iacopetta, BJ ;
Young, J ;
Walsh, T ;
Ward, R ;
Hawkins, N ;
Beranek, M ;
Jandik, P ;
Benamouzig, R ;
Jullian, E ;
Laurent-Puig, P ;
Olschwang, S ;
Muller, O ;
Hoffmann, I ;
Rabes, HM ;
Zietz, C ;
Troungos, C ;
Valavanis, C ;
Yuen, ST ;
Ho, JWC ;
Croke, CT ;
O'Donoghue, DP ;
Giaretti, W ;
Rapallo, A ;
Russo, A ;
Bazan, V ;
Tanaka, M ;
Omura, K ;
Azuma, T ;
Ohkusa, T ;
Fujimori, T ;
Ono, Y ;
Pauly, M ;
Faber, C ;
Glaesener, R ;
de Goeij, AFPM ;
Arends, JW ;
Andersen, SN ;
Lövig, T ;
Breivik, J ;
Gaudernack, G ;
Clausen, OPF ;
De Angelis, P ;
Meling, GI ;
Rognum, TO ;
Smith, R .
BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696
[7]   Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, JR ;
Clarke, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684
[9]   Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? [J].
Aretz, Stefan ;
Koch, Arend ;
Uhlhaas, Siegfried ;
Friedl, Waltraut ;
Propping, Peter ;
von Schweinitz, Dietrich ;
Pietsch, Torsten .
PEDIATRIC BLOOD & CANCER, 2006, 47 (06) :811-818
[10]   Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines [J].
Arnold, CN ;
Goel, A ;
Boland, CR .
INTERNATIONAL JOURNAL OF CANCER, 2003, 106 (01) :66-73